Fig. 2From: Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE studyProportion of patients experiencing injection-site reactions at baseline and Week 26. Responses at baseline were reported based on patients’ experience with prior injectors (4 weeks before entering into the study)Back to article page